Yajing Chen Sells 619 Shares of Zai Lab (NASDAQ:ZLAB) Stock

Posted by Francis Steltz on Aug 15th, 2026

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Get Free Report) CFO Yajing Chen sold 619 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $25.00, for a total transaction of $15,475.00. Following the completion of the sale, the chief financial officer directly owned 35,072 shares of the company’s stock, valued at $876,800. The trade was a 1.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Yajing Chen also recently made the following trade(s):

On Friday, June 26th, Yajing Chen sold 2,264 shares of Zai Lab stock. The shares were sold at an average price of $17.46, for a total transaction of $39,529.44.

Zai Lab Price Performance

Shares of ZLAB opened at $25.95 on Friday. The firm’s 50 day moving average is $19.58 and its 200-day moving average is $19.49. The stock has a market capitalization of $2.95 billion, a P/E ratio of -15.18 and a beta of 0.78. Zai Lab Limited Unsponsored ADR has a 12-month low of $15.96 and a 12-month high of $36.77.

Zai Lab (NASDAQ:ZLAB – Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported ($0.50) EPS for the quarter. Zai Lab had a negative return on equity of 27.43% and a negative net margin of 41.86%.The business had revenue of $106.31 million during the quarter. As a group, equities research analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.17 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on ZLAB. Citigroup upped their price target on Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a report on Friday, August 7th. Weiss Ratings raised Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. Zacks Research upgraded Zai Lab from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, Wall Street Zen lowered Zai Lab from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $40.20.

Get Our Latest Research Report on ZLAB

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Zai Lab stock. SG Americas Securities LLC increased its position in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Free Report) by 6.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,396 shares of the company’s stock after acquiring an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Zai Lab Company Profile

(Get Free Report)

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.